Tag Archive for: Krazati

Bristol Myers Squibb’s $4.8 billion acquisition of Mirati pays off with strong data from the KRYSTAL-12 study of Krazati, showing that the KRAS inhibitor significantly improves progression-free survival.

Frontier Medicines on Thursday closed its oversubscribed $80 million Series C funding round,  which it will use to advance its potentially first-in-class next-generation KRAS blocker FMC-376.

While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.

Mirati Therapeutics said on Friday the European medicines regulator’s panel has recommended approval of its treatment for a type of lung cancer.

Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.

Sanofi appears to be considering a buyout of cancer drugmaker Mirati Therapeutics, according to Bloomberg reporting on Thursday, citing sources familiar with the matter.

Eli Lilly presented the first clinical data on its KRAS G12 inhibitor at the American Association for Cancer Research (AACR) meeting in Orlando on Monday. Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

As we move into 2023, BioSpace takes a pause to reflect on the year gone by and some of the most remarkable news bits, looking at the top five noteworthy FDA drug and biologic therapy approvals in 2022.  

The agency’s top five represent an eclectic mix of cancer, cardiovascular and rare disease drugs.

Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.